Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bevacizumab--current status and future directions.

Rachel Midgley1, David Kerr

  • 1Department of Clinical Pharmacology and Cancer Therapeutics, Racliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK. Rachel.Midgley@cancer.org.uk

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|June 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumour-Associated Neutrophils in Colorectal Cancer: a Systematic Review, Meta-analysis, and Comprehensive Literature Review.

Journal of gastrointestinal cancer·2026
Same author

Clinical Effects of a Digital Health Intervention for Adults With Type 2 Diabetes in the United States: Retrospective Cohort Study.

Journal of medical Internet research·2026
Same author

Driving-Related Glucose Monitoring Practices Among Insulin-Treated Adults With Type 2 Diabetes.

Journal of diabetes science and technology·2026
Same author

Glucose Dysregulation in Hantavirus Infection: A Signal Worth Watching With Continuous Glucose Monitoring.

Journal of diabetes science and technology·2026
Same author

A Digital Diabetes Self-Management Education and Support Program Integrated With Continuous Glucose Monitoring for Type 2 Diabetes: Randomized Controlled Trial.

Journal of medical Internet research·2026
Same author

A Digital Diabetes Self-Management Education and Support Program Integrated With Continuous Glucose Monitoring Improves Glycemic Control: A Randomized Controlled Trial.

Journal of medical Internet research·2026

Bevacizumab, an anti-VEGF therapy, shows promise in treating advanced colorectal cancer and other solid tumors. Further research is needed to optimize dosing and patient selection for this angiogenesis inhibitor.

Area of Science:

  • Oncology
  • Cancer Biology
  • Vascular Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is vital for tumor growth, survival, and metastasis.
  • Vascular endothelial growth factor (VEGF) is a key driver of tumor angiogenesis.
  • Bevacizumab is a monoclonal antibody targeting VEGF, with demonstrated efficacy and a favorable safety profile.

Purpose of the Study:

  • To evaluate the efficacy and safety of Bevacizumab in advanced colorectal cancer.
  • To explore the potential of Bevacizumab in other solid tumors, including non-small cell lung cancer and renal cancer.
  • To identify optimal dosing strategies and patient selection criteria for Bevacizumab therapy.

Main Methods:

  • Phase III clinical trial in advanced colorectal cancer patients.

Related Experiment Videos

  • Assessment of Bevacizumab's efficacy and safety profile.
  • Review of ongoing and future clinical trials for other solid tumors.

    • Main Results:

    • Bevacizumab demonstrated proven efficacy in a phase III trial for advanced colorectal cancer.
    • The drug exhibits a reasonable safety profile.
    • Efficacy appears promising in non-small cell lung cancer, renal cancer, and other solid tumors.

    Conclusions:

    • Bevacizumab is an effective treatment option for advanced colorectal cancer.
    • The drug holds promise for various other solid tumors.
    • Further clinical trials are essential to determine optimal dosing and patient selection for Bevacizumab therapy to maximize clinical benefit.